[Primary pulmonary hypertension and its management].
Primary pulmonary hypertension (PPH) is a disease of un-known etiology that is characterized by an increase in pulmonary arterial pressure. Traditionally its treatment has been based on the administration of the vasodilator therapy with calcium channel blockers. At present there are some treatments which not only correct the vasoconstriction but also other pathogenic PPH associated effects, such a vascular remodelling and the thrombosis. These treatments include: a) analogs of prostacyclin with different administration routes; b) endothelin-receptor antagonists; and c) drugs that affect the metabolic pathway of nitric oxide. These pharmacological advances have reduced the number of pulmonary transplants in the patients with HPP, which is the last therapeutic alternative.
Crespo Martínez
C
C
Servicio de Farmacia, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria.
Morales León
V
V
Alonso Ramos
H
H
Alonso Ortiz
B
B
Molero Gómez
R
R
D000662:Amphetamines / Q000009:adverse effects; D002317:Cardiovascular Agents / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D004730:Endothelium, Vascular / Q000503:physiopathology; D006333:Heart Failure / Q000209:etiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D016040:Lung Transplantation; D009569:Nitric Oxide / Q000502:physiology; D010879:Piperazines / Q000627:therapeutic use; D044062:Prostaglandins I / Q000627:therapeutic use; D011651:Pulmonary Artery / Q000473:pathology; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D013927:Thrombosis / Q000209:etiology; D014661:Vasoconstriction
D000662:Amphetamines; D002317:Cardiovascular Agents; D065128:Endothelin Receptor Antagonists; D010879:Piperazines; D044062:Prostaglandins I; D011687:Purines; D013450:Sulfones; D009569:Nitric Oxide; D000068677:Sildenafil Citrate